" class="no-js "lang="en-US"> Modus Submits Patent Application for Sevuparin in Kidney Disease
Friday, June 09, 2023

Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease

Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that it has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease.

The patent application is based on novel preclinical work that was undertaken in an established kidney disease animal model during an academic collaboration project. A granted patent would provide patent protection until at least 2043.

Sevuparin is a proprietary compound of Modus Therapeutics, currently being evaluated in Phase 1 clinical trials as a potential treatment for sepsis and septic shock, as well as for severe malaria in children.

John Öhd, CEO of Modus Therapeutics, said: “Sevuparin is already in development as a potential new treatment for sepsis and septic shock. In addition, we are actively evaluating new avenues for development and commercialisation of our key asset, as well as continuously developing its patent portfolio in parallel. While the patent application is a tangible result of these efforts, it also demonstrates Modus´ ability to successfully collaborate internationally with leading academic institutions.”

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more